Portfolio Update

RNS Number : 4226J
Intl. Biotechnology Trust PLC
12 December 2022
 

 

 

 

 

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

 

 

Portfolio Update as at 12 December 2022

 

The Company notes that Amgen Inc (AMGN) has announced that it entered a definitive agreement to acquire IBT's portfolio company Horizon Therapeutics (HZNP) for $116.50 per share which represents a 47.9% premium to the closing price of Horizon on 29 November 2022 (being the last closing price per Company Share prior to the Company's issuance of an announcement of a possible offer under Rule 2.4 of the Irish Takeover Rules). The bid price in today's announcement represents a premium of 19.7% to the closing price as at 9 December 2022 of $97.29.

Prior to the announcement on 12 December 2022, IBT owned 479,973 shares in Horizon which represents 13.5% of IBT's Net Asset Value, as at the close on Friday 9 December.

 

For further information contact:

 

 

Company Secretary - Link Company Matters

 

Indu Shastri +44 (0)7936 045789

 

LEI: 213800N1QUJ744P76D11

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUBSBDDBDBDGDD

Companies

International Biotech Trust (IBT)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today